Menu

Sign in

Sign in

Contact us

Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Here's how too much calcium may lead to Parkinson's disease

Here's how too much calcium may lead to Parkinson's disease

Excess levels of calcium in brain cells may lead to the formation of toxic clusters that are the hallmark of Parkinson's disease, according to a study.

Impax launches authorized Solodyn generic

Impax launches authorized Solodyn generic

Impax Labs has launched its authorized Solodyn generic (minocycline HCl, extended-release tablets).

Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy

Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy

BRISBANE, Calif.

Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders

Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders

CAMBRIDGE, Mass.

Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases

Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases

CAMBRIDGE, Mass.

FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults

FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults

BRIDGEWATER, NJ, USA I February 19, 2018 I Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nerv...

H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine

H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine

CAMBRIDGE, MA, USA I February 20, 2018 I H3 Biomedicine Inc.

Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

SAN DIEGO, CA, USA I February 20, 2018 I Brickell Biotech, Inc.

Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis

Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis

SAN DIEGO, CA, USA I February 20, 2018 I Vical Incorporated (Nasdaq.

Scientists identify molecule that kills tumour cells, may help fight cancer PTI

Scientists identify molecule that kills tumour cells, may help fight cancer PTI

Humans need the chemical element selenium for good health.

Rheumatoid arthritis drugs market will grow to $30.4 billion by 2025

Rheumatoid arthritis drugs market will grow to $30.4 billion by 2025

The global rheumatoid arthritis drugs/therapeutics market size was valued at $20.

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

A new report published by Boston's Institute for Clinical and Economic Review (ICER) concludes that two pricey new CAR-T cell therapies, Novartis AG's Kymriah (tisagenlecleucel)...

58 59 60 616263 64 65 66

0 items in Cart

Cart Subtotal:

You will be able to Pay Online or Request a Quote